 |
PDBsum entry 5a85
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Med Chem
58:6151-6178
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.
|
|
P.Bamborough,
C.W.Chung,
R.C.Furze,
P.Grandi,
A.M.Michon,
R.J.Sheppard,
H.Barnett,
H.Diallo,
D.P.Dixon,
C.Douault,
E.J.Jones,
B.Karamshi,
D.J.Mitchell,
R.K.Prinjha,
C.Rau,
R.J.Watson,
T.Werner,
E.H.Demont.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor
outcomes in a number of different cancer types. To date, no potent and selective
inhibitors of the bromodomain have been reported. This article describes the
structure-based optimization of a series of naphthyridones from micromolar leads
with no selectivity over the BET bromodomains to inhibitors with sub-100 nM
ATAD2 potency and 100-fold BET selectivity.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |